Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO; H-share) disclosed a share repurchase on 24 April 2026, reducing its outstanding share count and increasing treasury stock as follows:

• Transaction details: 36,300 H-shares were bought back on the Hong Kong Stock Exchange at prices ranging from HKD 28.00 to HKD 31.36, for a total consideration of HKD 1.06 million. The volume-weighted average cost stands at HKD 29.14 per share.

• Capital structure impact: Issued shares (excluding treasury shares) fell 0.03% from 135.91 million to 135.88 million. Treasury shares rose from 304,200 to 340,500, keeping total issued shares unchanged at 136.22 million.

• Utilisation of repurchase mandate: The company is authorised to buy back up to 13.62 million shares. Cumulative purchases under this mandate now total 340,500 shares, equal to 0.25% of the authorised amount.

• Governance and compliance: The board-sanctioned repurchase complied with Hong Kong Listing Rules and domestic regulations. A 30-day moratorium on new share issues or treasury-share sales applies until 24 May 2026.

The disclosure was signed by Chairman and Executive Director Mr Zhang Faming on 24 April 2026.